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Cellular functions depend on numerous protein-coding and noncoding RNAs and the RNA-binding
proteins associated with them, which form ribonucleoprotein complexes (RNPs). Mutations that
disrupt either the RNA or protein components of RNPs or the factors required for their assembly
can be deleterious. Alternative splicing provides cells with an exquisite capacity to fine-tune their
transcriptome and proteome in response to cues. Splicing depends on a complex code, numerous
RNA-binding proteins, and an enormously intricate network of interactions among them, increasing
the opportunity for exposure to mutations and misregulation that cause disease. The discovery of
disease-causingmutations in RNAs is yielding awealth of new therapeutic targets, and the growing
understanding of RNA biology and chemistry is providing new RNA-based tools for developing
therapeutics.the splicing of the transcript produced from the same gene (in
cis) as well as mutations in the splicing machinery and the regu-
latory proteins that affect splicing of other transcripts (in trans).
The discovery of new disease-causing mutations in RNAs
provides a range of therapeutic targets, and the continuing eluci-
dation of RNA biochemistry is also yielding new tools that can be
exploited in the development of RNA-based therapeutics.
In humans and other complex metazoans, the vast majority of
protein-coding genes contain many segments (introns) that are
part of the primary transcript (pre-mRNA) but are not included
in the mRNA. The removal of introns and the joining together of
the sequences included in the mRNA (exons) that contain the
protein-coding open reading frame and the 30 and 50 untrans-
lated regions (UTRs) is accomplished by pre-mRNA splicing.
Splicing must be both rapid and precise, a demanding feat
considering that introns are typically much larger than exons
and are strewn with translation termination codons, which would
result in truncated proteins if not accurately removed. The defini-
tion of exons and the execution of the splicing reaction are medi-
ated by the spliceosome, a large and modular molecular
machine composed of snRNAs and splicing factors, and by
numerous RNA-binding proteins (see Review by M.C. Wahl,
C.L. Will, and R. Luhrmann on page 701 of this issue). The
biosynthetic and metabolic energy cost of splicing and of the
surveillance necessary to eliminate imprecisely spliced mRNAs
is very high, and so is the potential harm from defects in these
processes. It was therefore not self-evident at the outset why
splicing arose, persisted, and expanded in the number and
size of introns with the evolution of more complex organisms.
The real payoff of splicing, which complex organisms have
evolved to capitalize on (or perhaps capitalized on for their evolu-
tion), seems to come from the capacity for alternative splicing.Introduction
The normal function of cells depends on accurate expression of
a large number of protein-coding RNAs (messenger RNAs
[mRNAs]) and noncoding RNAs. These RNAs participate in tran-
scription (e.g., 7SK RNA), RNA processing (e.g., small nuclear
RNAs [snRNAs], small nucleolar RNAs [snoRNAs]) and transla-
tion (e.g., ribosomal RNAs [rRNAs], transfer RNAs [tRNAs],
7SL/SRP RNA, microRNAs [miRNAs]). There are many other
RNAs that are involved in other processes (e.g., telomerase,
MRP, RNase P RNAs), and those whose functions are less well
characterized or entirely unknown (e.g., vault RNAs, Y RNAs,
Piwi-interacting RNAs [piRNAs]). RNAs exist in cells as ribonu-
cleoprotein complexes (RNPs) that are composed of one or
more RNAs and typically numerous RNA-binding proteins (Drey-
fuss et al., 1993; Glisovic et al., 2008). The RNPs are the func-
tional forms of the corresponding RNAs, and their normal activity
depends on both the specific composition and the precise
arrangement of their protein constituents. As there are numerous
RNAs and a very large number of RNA-binding proteins, the
biogenesis of RNPs must be orchestrated with great fidelity.
Mutations that disrupt any of the components of RNPs, either
RNAs or proteins, or the factors required for their assembly
can be deleterious to cells and cause disease (Lukong et al.,
2008; Wang and Cooper, 2007). Examples of such cases are
now too numerous to afford a meaningful discussion of all but
a few within the space constraints of this article. We focus here
on defects in pre-mRNA splicing as these have emerged as
a common disease-causingmechanism underlyingmany human
genetic ailments. For a more general perspective, a summary of
representative examples of disease-causing defects associated
with other types of RNAs or RNPs is listed in Table 1. Here, we
discuss several diseases that result from mutations that affectCell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 777
Table 1. Trans-Acting Mutations Affecting RNA-Dependent Functions that Cause Disease
Disease Gene/Mutation Function
Prader Willi syndrome SNORD116 ribosome biogenesis
Spinal muscular atrophy (SMA) SMN2 splicing
Dyskeratosis congenita (X-linked) DKC1 telomerase/translation
Dyskeratosis congenita (autosomal dominant) TERC telomerase
Dyskeratosis congenita (autosomal dominant) TERT telomerase
Diamond-Blackfan anemia RPS19, RPS24 ribosome biogenesis
Shwachman-Diamond syndrome SBDS ribosome biogenesis
Treacher-Collins syndrome TCOF1 ribosome biogenesis
Prostate cancer SNHG5 ribosome biogenesis
Myotonic dystrophy, type 1 (DM1) DMPK (RNA gain of function) protein kinase
Myotonic dystrophy, type 2 (DM2) ZNF9 (RNA gain of function) RNA binding
Spinocerebellar ataxia 8 (SCA8) ATXN8/ATXN8OS (RNA gain of function) unknown/noncoding RNA
Huntington’s disease-like 2 (HDL2) JPH3 (RNA gain of function) ion channel function
Fragile X-associated tremor ataxia syndrome (FXTAS) FMR1 (RNA gain of function) translation/mRNA localization
Fragile X syndrome FMR1 translation/mRNA localization
X-linked mental retardation UPF3B translation/nonsense-mediated decay
Oculopharyngeal muscular dystrophy (OPMD) PABPN1 30 end formation
Human pigmentary genodermatosis DSRAD editing
Retinitis pigmentosa PRPF31 splicing
Retinitis pigmentosa PRPF8 splicing
Retinitis pigmentosa HPRP3 splicing
Retinitis pigmentosa PAP1 splicing
Cartilage-hair hypoplasia (recessive) RMRP splicing
Autism 7q22-q33 locus breakpoint noncoding RNA
Beckwith-Wiedemann syndrome (BWS) H19 noncoding RNA
Charcot-Marie-Tooth (CMT) Disease GRS translation
Charcot-Marie-Tooth (CMT) Disease YRS translation
Amyotrophic lateral sclerosis (ALS) TARDBP splicing, transcription
Leukoencephalopathy with vanishing white matter EIF2B1 translation
Wolcott-Rallison syndrome EIF2AK3 translation (protease)
Mitochondrial myopathy and sideroblastic anemia (MLASA) PUS1 translation
Encephalomyopathy and hypertrophic cardiomyopathy TSFM translation (mitochondrial)
Hereditary spastic paraplegia SPG7 ribosome biogenesis
Leukoencephalopathy DARS2 translation (mitochondrial)
Susceptibility to diabetes mellitus LARS2 translation (mitochondrial)
Deafness MTRNR1 ribosome biogenesis (mitochondrial)
MELAS syndrome, deafness MTRNR2 ribosome biogenesis (mitochondrial)
Cancer SFRS1 splicing, translation, export
Cancer RBM5 splicing
Multiple disorders mitochondrial tRNA mutations translation (mitochondrial)
Cancer miR-17-92 cluster RNA interference
Cancer miR-372, miR-373 RNA interference778 Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc.dent patterns. This elaborate scheme shifts the balance of
control of gene expression from largely transcriptional, the
production of a colinear transcript of DNA, to a largely posttran-
scriptional nonlinear complex and intricate processing of the
pre-mRNA. Recent studies with high-throughput deep
sequencing indicate that the extent of alternative splicing and
thus spliced isoforms is much greater in humans than wasAlternative splicing allows individual genes to express multiple
mRNAs and encode numerous proteins that differ by either large
or small peptides or have different UTRs. Alternative splicing
provides tremendous opportunities for enrichment of the tran-
scriptome and proteome without the need for expansion of the
genome. Importantly, alternative splicing can also be regulated
differently in cell type-, developmental stage-, or signal-depen-
previously estimated (Pan et al., 2008; Wang et al., 2008). In
some cases, a large number of splicing events are required to
produce an mRNA, and the number of splicing options can be
vast. Examples of proteins encoded by human genes containing
a large number of exons include Titin (Ttn; 316 exons), the ryano-
dine receptor 1 (Ryr1; 106 exons), and dystrophin (DMD; 79
exons). However, with this enormous increase in complexity
comes an increased susceptibility tomalfunction. Indeed, a large
number of human diseases result from mutations or misregula-
tion of the splicing process.
The major splicing apparatus (spliceosome) is composed of
five small nuclear ribonucleoprotein complexes (snRNPs) each
containing one or two snRNAs (U1, U2, U4/U6, and U5) and
numerous (likely more than 100) protein factors. These protein
factors include RNA-binding proteins (e.g., U2AF, SF1, and
SRFs) and enzymes (helicases/RNPases, kinases and phospha-
tases, etc.). These modulate the structure and the orderly step-
wise associations, dissociations, and conformational transitions
of the pre-mRNA, snRNAs, and protein complexes to facilitate
the splicing reaction, proofreading, and substrate release (Nil-
sen, 2003; Staley and Guthrie, 1998; Will and Luhrmann, 2001).
A minor splicing pathway, the unique components of which are
about 100-fold less abundant than those in the major splicing
pathway, operates in parallel using a similar scheme, but it
recognizes different canonical splice site sequences and uses
mostly different snRNAs (U11, U12, U4atac/U6atac, and U5)
(Patel and Steitz, 2003). Each snRNP, except U6 and U6atac,
has in common a stable seven-membered ring of Sm proteins
(the Sm core), which forms around a conserved sequence called
the Sm site, as well as several snRNA-specific proteins. The
biogenesis of snRNPs is a highly complex process involving
export of the nascent pre-U snRNAs to the cytoplasm, where
assembly of Sm cores takes place and, after processing of the
snRNAs, reimport of the snRNPs to the nucleus to function in
splicing. Sm core assembly is not a spontaneous process, but
rather is directed by the SMN (survival of motor neurons)
complex. This complex is an ATP-dependent assemblyosome
composed of the SMN protein, Gemins 2–8, and Unrip, which
specifically identifies snRNAs and brings them together with
Sm proteins. This recognition is aided by a specific arginine
modification on Sm proteins mediated by the methylosome/
PRMT5 (Neuenkirchen et al., 2008; Yong et al., 2004). Consider-
able insight into this pathway has come from studies of a devas-
tating disease in which its namesake protein, SMN, is deficient.
Pre-mRNAs contain a ‘‘splicing code’’ made up of loosely
defined consensus sequences that define the splice junctions
and a bewildering number and diversity of relatively short cis-
acting elements within exons aswell as introns (Wang andBurge,
2008). TheseelementsareboundbyRNA-bindingproteins,which
have either positive (primarily SR proteins) or negative (primarily
hnRNPproteins) effects on spliceosome assembly in their vicinity
tomaintainappropriateconstitutivesplicingor to regulatealterna-
tive splicing. Cells contain a large assortment of these RNA-
binding proteins, and their relative stoichiometries play important
roles indeterminingsplicingoutcomes formanygenes (Smith and
Valcarcel, 2000). The repertoire of these is unique toeachcell type
and thus the regulation of expression and activity of these
proteins is critical for normal alternative splicing. Thus, in additionto diseases caused by mutations in exons, including missense,
nonsense, and frame-shift mutations in the open reading frame,
which give rise to defective proteins, and mutations in UTRs
that affect translation efficiencyormRNAstability, a large number
of diseases are now known to result from intronic or exonicmuta-
tions that disrupt normal splicing patterns.
Cotranscriptionally, pre-mRNAs become associated with
numerous RNA-binding proteins (hnRNP proteins) that influence
their structure and interactions and play key roles in their splicing
and polyadenylation. Upon splicing, additional proteins are
acquired at the splice junctions (the exon junction complex
[EJC]) and numerous proteins are removed, and the metamor-
phosis of the mRNA-protein complexes (mRNPs) continues
as they transit to the cytoplasm (Figure 1) (Dreyfuss et al., 2002;
Maquat, 2004; Tange et al., 2004). Many of these proteins shuttle
between the nucleus and the cytoplasm (Pinol-Roma and Drey-
fuss, 1992), including hnRNP proteins and SR (serine-arginine-
rich domain-containing) proteins. The functions they perform in
the nucleus are not their last, as they also have roles in mRNA
translation, stability, and localization in the cytoplasm. RNA edit-
ing provides yet another mode to increase the complexity of the
transcriptome (Schaub and Keller, 2002), and a further layer of
regulation has now been revealed with the discovery of miRNAs,
an abundant class of noncoding RNAs that regulate mRNA
translation and stability (Valencia-Sanchez et al., 2006). The
large number of proteins and regulatory RNAs in posttranscrip-
tional RNA processing and the enormously intricate network of
interactions among them provide cells with exquisite capacity
to fine-tune their transcriptome and rapidly adjust their proteome
in response to stimuli, but it also increases exposure to muta-
tions and extends their vulnerability to misregulation that causes
numerous diseases, particularly neuromuscular and neurode-
generative diseases and cancer.
Mutations that Cause Splicing Defects in Disease
Cis-Acting Mutations that Disrupt Splicing
Three consensus sequences are found at all exon-intron bound-
aries: the 50 and 30 splice sites at the 50 and 30 ends of the intron,
respectively, and the branch point sequence (BPS), which is typi-
cally located within 30–50 nucleotides upstream of the 30 splice
site. These sequences contain a considerable amount of the
information required for precise exon joining (estimated to be
about half in some cases [Lim and Burge, 2001]) and are recog-
nized through RNA-RNA and RNA-protein interactions with
components of the spliceosome. The 50 splice site binds to the
U1 snRNP early during spliceosome assembly, then to U6
snRNP; the BPS binds SF1 and then U2 snRNP, and U2AF binds
near the 30 splice site. Mutations within the sequences that
disrupt these interactions are responsible for 9%–10% of the
genetic diseases that are caused by point mutations (Cartegni
et al., 2002; Wang and Cooper, 2007). The remaining information
required for splicing is contained within relatively short (6
nucleotide) sequences located within both exons and introns
that either enhance or suppress splicing (Wang and Burge,
2008). Exonic splicing enhancers (ESEs) and exonic splicing
silencers (ESSs) activate or repress splicing, respectively, from
within exons, while intronic splicing enhancers (ISEs) and
silencers (ISSs) function from within introns. In contrast to theCell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 779
consensus splice sites, which are relatively well defined in
sequence and position, the intricate code formed by these auxil-
iary splicing elements is only partially understood. While a signif-
icant portion of the code has been deciphered, it is not yet
possible to determine from genomic sequence whether
a disease-associated mutation will disrupt splicing. This is the
case in part because these elements are composed of diverse
Figure 1. The mRNA Biogenesis Pathway and Posttranscriptional
Gene Regulation
Overview of the dynamic interactions of the major RNPs involved in pre-mRNA
processing, mRNA biogenesis, and regulation of gene expression. The
nascent transcript (pre-mRNA), capped with a 7-methyl guanosine (m7G)
cap, is bound by hnRNP proteins and SR (serine-arginine-rich domain-con-
taining) proteins. Small nuclear ribonucleoprotein particles (snRNPs) bind to
the splice sites at the 50 and 30 ends of introns. The spliced introns are excised
as lariats, which are then debranched and degraded. The exon junction
complex (EJC) assembles on spliced mRNA 20 nucleotides upstream of
joined exons, followed by the export of themRNA to the cytoplasm.MicroRNAs
(miRNAs) in the form of ribonucleoprotein complexes (miRNPs) bind to target
mRNAs to regulate translation and mRNA stability. The poly(A)-binding protein
(PABP) binds to the poly(A) tail of cytoplasmic mRNAs. The SR domains are
indicated with a star. cEJC indicates the remaining stable EJC on mRNA in
the cytoplasm, which is removed by translating ribosomes.780 Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc.classes of sequences, the full complement of which remains to
be identified. There is also an incomplete understanding of the
subtleties of the code, including extensive interdependency
between andwithin elements (Roca et al., 2008). These elements
function through interactions with RNA-binding proteins, and
while the preferred binding sites for more than 40 proteins are
known, primarily for SR and hnRNP proteins (Gabut et al.,
2008), cognate binding proteins have been identified for only
a minority of the growing list of putative splicing elements.
Essentially all exons, whether alternatively or constitutively
spliced, contain splicing elements (Wang and Burge, 2008). As
a result, exons are a virtual minefield with regard to the effects
of nucleotide substitutions on splicing. Up to 25% of synony-
mous (in terms of amino acid coding) substitutions can disrupt
normal splicing, as can nonsynonomous and termination codons
(Pagani et al., 2005), emphasizing the importance of considering
silent mutations as mediators of pathogenic effects. For some
genes, up to 50% of point mutations within exons affect splicing,
and it has been hypothesized that more than half of known
disease-causing mutations disrupt splicing (Lopez-Bigas et al.,
2005). A large number of exonic mutations that result in aberrant
splicing have been documented (Cartegni et al., 2002; Wang and
Cooper, 2007). Particularly instructive are disease-causing
exonic mutations that have been studied extensively and have
become focal points for various RNA-based therapeutic
approaches.
A striking example of the detrimental effect that mutations in
exonic splicing signals can have is a single nucleotide substitu-
tion in the survival of motor neuron 2 (SMN2) gene and its critical
role to spinal muscular atrophy (SMA) (Lefebvre et al., 1995).
SMN is a ubiquitously expressed protein that plays a critical
role in snRNP biogenesis and is essential for viability of all cells
in divergent eukaryotes (Neuenkirchen et al., 2008; Yong et al.,
2004). SMA is a common, often fatal, motor neuron degenerative
disease and a leading genetic cause of infant mortality (Talbot
and Davies, 2001; Wirth et al., 2006). SMA severity corresponds
to the degree of functional SMN protein deficiency. In humans,
there are two SMN genes, SMN1 and SMN2, both of which
encode the same open reading frame. The vast majority of
SMA patients have deletions of the SMN1 gene but retain
SMN2, exposing the functional deficiency of a single nucleotide
substitution, a C/T change at position 6 in exon 7 ofSMN2. This
mutation, though it does not change the amino acid coding,
significantly alters the splicing pattern of the SMN2 pre-mRNA,
causing frequent skipping of exon 7 that produces an inactive
and unstable protein lacking the last 16 amino acids
(Figure 2A). Thus, SMN2 is much less effective than SMN1 in
producing SMN protein (Wirth et al., 2006). Two models have
been proposed to explain exon 7 skipping in SMN2. One is
that the substitution disrupts an ESE, which the splicing acti-
vator, ASF/SF2 binds (Cartegni and Krainer, 2002), and the other
is that it creates an ESS to which the splicing suppressor hnRNP
A1 binds (Kashima and Manley, 2003; Kashima et al., 2007).
Though they appear to be contradictory, these models, in fact,
are compatible (Cartegni et al., 2006) and underscore the precar-
iousness of splicing signals in that a single nucleotide change
can convert an ESE into an ESS. It is intriguing that critical
RNA binding sites for ubiquitous, abundant but functionally
Figure 2. Mutations Disrupting the Cis-
Acting Splicing Code Cause Splicing
Defects and Disease
(A) The motor neuron degenerative disease SMA
results from deletion of the SMN1 gene. The re-
maining SMN2 gene has a C/T substitution in
exon 7 that inactivates an exonic splicing
enhancer (ESE), and creates an exonic splicing
silencer (ESS), leading to exon 7 skipping and
a truncated protein (SMND7).
(B) A T/A substitution in exon 31 of the dystro-
phin gene simultaneously creates a premature
termination codon (STOP) and an ESS, leading to
exon 31 skipping. This mutation causes a mild
form of DMD because the mRNA lacking exon 31
produces a partially functional protein.
(C)Mutations within and downstream of exon 10 of
the MAPT gene encoding the tau protein affect
splicing regulatory elements and disrupt the
normal 1:1 ratio of mRNAs including or excluding
exon 10. This results in a perturbed balance
between tau proteins containing either four or
three microtubule-binding domains (4R-tau and
3R-tau, respectively), causing the neuropatholog-
ical disorder FTDP-17. The example shown is the
N279K mutation, which enhances an ESE func-
tion, promoting exon 10 inclusion and shifting the
balance toward increased 4R-tau.
(D) Polymorphic (UG)m(U)n tracts within the 30
splice site of the CFTR gene exon 9 influence the
extent of exon 9 inclusion and the level of full-
length functional protein, modifying the severity
of cystic fibrosis (CF) caused by a mutation else-
where in the CFTR gene.coding for one spectrin-like repeat but retain the correct reading
frame to produce a partially functional protein, explaining why an
individual harboring this mutation has a milder form of the
disease than would be expected given the presence of a PTC.
In this example, the specific mechanism of pathogenesis would
have been missed if only the PTC mutation detected in genomic
DNA had been considered, demonstrating the need to determine
the effects of mutations on splicing directly by using RNA
from the affected tissues. Examples such as this one also sug-
gested the potential therapeutic benefits of inducing exon
skipping to restore reading frame (see below).
As another example, mutations within and downstream from
the alternatively spliced exon 10 of the microtubule-associated
protein tau (MAPT) gene encoding the tau protein disrupt the
1:1 ratio required for mRNAs that include or exclude this exon.
Exon 10 encodes the fourth of four microtubule-binding domains
(R), and disruption of the balance between 4R-tau and 3R-tau
isoforms (Figure 2C) results in hyperphosphorylation and aggre-
gation of tau proteins into neurofibrillary tangles that are hall-
marks of several neurodegenerative diseases such as Alz-
heimer’s disease (AD). This exon and surrounding introns are
dense with splicing regulatory elements, which is indicative of
the degree to which splicing of this exon is controlled. Numerous
mutations within and around MAPT exon 10 disrupt exonic and
intronic splicing elements and cause the inherited neuropatho-
logical disorder frontotemporal dementia with Parkinsonismopposing splicing factors differ by a single nucleotide, and it can
be anticipated that there are many more cases where splicing is
altered because of the ease with which the balance of positively
and negatively acting splicing factors (ASF/SF2-hnRNP A1, and
many others) can be shifted. Because of its critical function in the
biogenesis of snRNPs and splicing regulation, this SMN2 substi-
tution has significant ramifications to splicing (described below).
The massive (2.4 Mb) dystrophin gene, most of which is in its
78 introns, is a splicing accident waiting to happen, and it does
with an incidence of 1:3000 of male births in Duchenne muscular
dystrophy (DMD). DMD is caused by loss-of-function mutations,
and while more than 65% of DMD mutations are genomic dele-
tions, a large number of exonic and intronic point mutations
cause disease through aberrant splicing. Dystrophin is posi-
tioned at the cytoplasmic side of the skeletal muscle sarco-
lemma, where it communicates signals between the extracellular
matrix and the cellular contractile apparatus and it stabilizes the
cell membrane, which must withstand repeated contraction-
induced distortions. The protein contains four domains: an
actin-binding domain at the N terminus, a linker region of 24
spectrin-like repeats, a cysteine rich domain, and a C-terminal
domain (Nowak and Davies, 2004). A particularly revealing
T/A substitution in exon 31 not only creates a premature termi-
nation codon (PTC), but also introduces an ESS that binds to
hnRNP A1, resulting in partial exon skipping (Disset et al.,
2006) (Figure 2B). Interestingly, mRNAs lacking this exon loseCell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 781
linked to chromosome 17 (FTDP-17), demonstrating a direct
relationship between aberrant tau expression due to alternative
splicing disruption and neuropathology (Liu and Gong, 2008).
Also high on the menu of disease-causing splicing mutations
is the cystic fibrosis transmembrane conductance regulator
(CFTR) gene, which encodes a transmembrane chloride channel
required for proper function of secretory epithelium in multiple
tissues including lung, small intestine, and testes. A tryptophan
deletion (DF508) causes a severe loss of CFTR protein function
that is responsible for more than 50% of the cases of cystic
fibrosis (CF) in the United States. Scores of mutations elsewhere
in the gene produce milder forms of the disease (atypical CF);
however, individuals with the same mutation were found to
exhibit significant differences in disease severity. One mecha-
nism for these differences was found to involve polymorphic
(UG)m and (U)n tracts within the 30 splice site of CFTR exon 9,
which exhibits slight exon skipping even from the normal allele
in unaffected individuals. Individuals with a longer (UG)m tract
exhibit more exon skipping in part through increased binding
of TDP-43 (Figure 2D) (Buratti et al., 2004). The severity of the
effects of mutations elsewhere in the CFTR gene is modulated
by the level of exon 9 inclusion and ultimately the amount of
full-length functional protein that is expressed.
Splicing as a Modifier of Disease Susceptibility
and Severity
Genetic variation is the predominant determinant of individual
phenotypic differences, including those that are relevant to
disease: disease severity (modifiers), disease susceptibility,
development of the multigenic common diseases, and differ-
ences in positive and negative responses to therapeutic
compounds. Recent results indicate an unexpected level of vari-
ability in the expression of different splice variants between indi-
viduals, strongly suggesting a significant role for splicing in
phenotypic differences that are relevant to disease (Graveley,
2008; Wang and Cooper, 2007). An early estimate of the effects
of genetic variation on splicing found that up to21% of alterna-
tively spliced genes could be influenced by local polymorphisms
(Nembaware et al., 2004). Combined analyses of mRNA expres-
sion (including splicing differences) using exon tiling microarrays
linked with polymorphism determination using the CEU HapMap
revealed that genetic variants affected differences in mRNA
structure due to alternative splicing and in 50 and 30 end selection
more than differences in whole gene mRNA levels (Kwan et al.,
2008). Particularly telling is a recent analysis using deep
sequencing for global quantification of alternative splice variants
in cerebellar tissue from six individuals that revealed that up to
30% of the splicing events exhibited individual-specific differ-
ences reflective of striking variability in cis- as well as trans-
acting splicing environments (Wang et al., 2008). These studies
strongly support the contention that polymorphisms located
within introns and exons have a significant impact on individual
variation of gene expression at the level of RNA processing
and strongly contribute to individual differences in disease
severity, susceptibility, and therapeutic responses. The future
goal of providing personalized medicine will require a complete
understanding of the effects of genetic variation on the splicing
code as well as on the nuclear splicing machinery that interprets
the code.782 Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc.Disease-Causing Defects in the Splicing Machinery
Mutations in the constituents of the splicing machinery or any of
the trans-acting splicing components and their regulators have
the potential to affect expression of a large number of genes,
directly or through secondary effects. Important themes that
have emerged over the past several years are that mutations in
ubiquitous spliceosome components and splicing factors can
cause tissue-specific pathogenesis, and that changes in the
relative stoichiometry of general splicing factors can cause
profound changes in splicing patterns and cause disease.
Splicing abnormalities have been found to be particularly preva-
lent in neurodegenerative disease and in cancer. Though
specific causality in many cases is difficult to prove, this obser-
vation brings to the forefront the enormous vulnerability of
splicing, its potential pathogenicity, and the potential utility of
splicing patterns as signatures (biomarkers) of specific diseases
and as targets for therapeutic intervention.
Mutations in Spliceosome Components
Although the spliceosome is composed of a large number of
proteins and five snRNPs, very few mutations in core spliceo-
some components have been found, suggesting that such
mutations are incompatible with life either at the cellular level
or in early development. Interestingly, mutations in four proteins
(PRPF31, PRPF8, PRPF3, RP9) are associated with disruption
of basal spliceosome function, and all cause autosomal domi-
nant forms of retinitis pigmentosa (RP) (Mordes et al., 2006).
All four proteins are components of the U4/U5/U6 tri-snRNP
complex, which joins the assembling spliceosome to form the
catalytic center. Dominant inheritance suggests that haploin-
sufficiency does not provide a sufficient level of spliceosome
function in photoreceptor neurons, the affected cells. For
example, although a general defect in splicing was not de-
tected in lymphoblast cell lines derived from RP patients con-
taining null alleles for PRPF31 (Rivolta et al., 2006), specific
pre-mRNAs were found to be sensitive to PRPF31 mutations
in transient expression assays (Mordes et al., 2007). The
intriguing sensitivity of photoreceptor neurons could reflect an
inability to produce sufficient levels of highly expressed
mRNAs, such as those from the rhodopsin gene (mutations in
this gene also cause dominant forms of the disease). However,
alternative mechanisms are possible, such as photoreceptor-
specific sensitivity to aggregates formed from accumulation
of mutant proteins (Mordes et al., 2007).
Changes in the snRNP Repertoire and Splicing
Abnormalities in SMA
The best-characterized function of the SMN complex is its
essential role in the biogenesis of snRNPs (Neuenkirchen et al.,
2008; Yong et al., 2004). SMNdeficiency causes a corresponding
deficit in snRNP assembly capacity (Wan et al., 2005). Motor
neuron developmental abnormalities could be rescued by injec-
tion of purified snRNPs in SMN-deficient zebrafish embryos
(Winkler et al., 2005), and reduced snRNP assembly has been
demonstrated in an SMN-deficient SMA mouse model (Gaba-
nella et al., 2007; Zhang et al., 2008b). Recent studies in these
mice also revealed profound perturbations in RNA metabolism,
including changes in snRNAs and numerous splicing abnormal-
ities (Zhang et al., 2008b). Surprisingly, instead of a uniform
decrease in the steady-state levels of all the snRNAs, each
Splicing Factors in Disease: Mutations and Changes
in Stoichiometry
Like themajor spliceosomal snRNPs,many of the hnRNP andSR
proteins that regulate splicing are present in vast excess over
their high-affinity binding sites on pre-mRNAs (Dreyfuss et al.,
1993, 2002). Yet, even moderate changes in expression of one
of them, and hence their relative stoichiometry, can have signif-
icant effects on alternative splicing (Caceres and Kornblihtt,
2002; David and Manley, 2008; Martinez-Contreras et al.,
2007; Smith and Valcarcel, 2000). Furthermore, many of the
hnRNP and SR proteins shuttle continuously between the
nucleus and the cytoplasm (Caceres et al., 1998; Pinol-Roma
and Dreyfuss, 1992), and their subcellular distribution can shift
in response to stress signals. The resulting change in stoichiom-
etry of splicing factors in the nucleus could also modulate alter-
native splicing patterns. A diverse set of diseases are associated
with changes in expression of RNA-binding proteins involved in
splicing and splicing regulation (Gabut et al., 2008; Lukong
et al., 2008; Ule, 2008).
Recent studies suggest a role for several RNA-binding
proteins in neurological and psychiatric diseases. TDP-43,
initially identified as binding to the HIV trans-acting response
element (TAR), and shown to be a transcriptional repressor of
HIV, is an hnRNP protein similar in general structure to hnRNP
A1 and A2. It has been found to have several different associa-
tions with disease (Buratti and Baralle, 2008). In one, TDP-43
binds to the polymorphic (UG)m repeats within intron 8 of the
pre-mRNA of CFTR (the gene mutated in cystic fibrosis) such
that increased binding to longer (UG)m repeats causes
increased exon 9 skipping. Recent studies have shown that
TDP-43, which is normally nuclear, is found in cytoplasmic inclu-
sions in affected regions of the brains of individuals with fronto-
temporal dementia (FTD), Alzheimer’s disease, and amyotrophic
lateral sclerosis (ALS) (Ule, 2008). In these patients, TDP-43 is
depleted from nuclei and the protein that accumulates in the
cytoplasmic inclusions is ubiquitinated, cleaved, or abnormally
phosphorylated. These findings represent a significant advance
and a useful histological marker that correlates well with FTD.
Mutations in the TARDBP gene, which encodes TDP-43, also
are associated with both sporadic and familial forms of ALS,
demonstrating a role for TDP-43 in the pathogenesis of neuro-
logical diseases (Daoud et al., 2008; Kabashi et al., 2008; Ruth-
erford et al., 2008; Sreedharan et al., 2008). It remains to be
determined whether the pathogenic mechanism relates to
toxicity of the cytoplasmic aggregates, loss of TDP-43’s nuclear
function, or a combination of both.
Another RNA-binding protein that has recently been impli-
cated in neurological disorders is quaking (QKI). QKI is the
human homolog of the gene mutated in the spontaneous mouse
dysmyelination mutant, quaking viable (qkv). The protein is
a member of the STAR family, which contains domains that
link RNA bindingwith signal transduction. QKI expresses nuclear
and cytoplasmic isoforms via alternative splicing, and it regu-
lates both splicing and mRNA stability; putative pre-mRNA and
mRNA targets have been identified (Chenard and Richard,
2008). QKI expression in oligodendrocytes is required for normal
myelination in mice, and it plays a fundamental role in differenti-
ation of oligodendrocyte precursor cells in culture for which RNAsnRNA is affected differently in every tissue of SMN-deficient
mice, resulting in different snRNA stoichiometries and an altered
snRNP repertoire in every tissue (Gabanella et al., 2007; Zhang
et al., 2008b). In addition, the SMN deficiency causes wide-
spread and cell type-specific splicing abnormalities affecting
numerous mRNAs of functionally diverse genes, including shifts
in the ratios of known alternatively spliced isoforms as well as
many splicing defects of constitutive exons (Zhang et al.,
2008b). Knockdown of spliceosomal proteins in yeast and
Drosophila have shown that depletion of general and constitutive
components of the splicing machinery can have differential
effects on splicing of specific pre-mRNAs and on alternative
splicing (Clark et al., 2002; Park et al., 2004; Pleiss et al.,
2007). Although the mechanism behind the splicing defects in
SMN deficiency is unknown and SMN is not itself a splicing
factor, it is reasonable to consider the possibility that changes
in the snRNP repertoire affect the efficiency, rate, and fidelity
of spliceosome assembly on different introns. Alternatively, or
in addition, SMN may have direct roles in splicing.
These observations illustrate how a deficiency in a ubiqui-
tously expressed housekeeping protein may cause tissue-
specific outcomes and invite a new perspective on the patho-
physiology of the disease SMA. A conundrum in SMA has
been to reconcile the known housekeeping function of SMN
with the apparent selectivity of SMA pathogenesis to motor
units (anterior horn amotor neurons and the muscles they inner-
vate). It is likely that tissue-specific factors functioning in
concert with SMN determine a cell’s snRNP repertoire.
Because each cell type has a unique assortment of splicing
factors and SMN deficiency causes its snRNP repertoire to
change in a unique way, the resulting perturbations are distinct
and give rise to cell type-specific effects on splicing. These find-
ings also reveal a key role for the SMN complex in RNA metab-
olism and splicing regulation and indicate that SMA involves
splicing abnormalities throughout the organism, and not only
in motor units. Although recent studies suggest that the extent
of alternative splicing is much greater than was previously
believed, it is nevertheless clear that each tissue produces
a consistent pattern of alternatively spliced mRNA isoforms
(Castle et al., 2008; Pan et al., 2008; Wang et al., 2008). It is
thus not apparent why other tissues in the SMA mice do not
show overt pathology despite numerous splicing abnormalities.
The extent to which abnormal mRNAs are translated will need
to be determined to address this issue. In addition to SMN’s
role in snRNP biogenesis, it likely plays a role in the biogenesis
or function of other RNPs, possibly including complexes con-
taining the Sm-like proteins (Lsm proteins) with which it inter-
acts, as well as snoRNPs, hnRNPs, and mRNPs (Neuenkirchen
et al., 2008; Rossoll et al., 2003; Yong et al., 2004; Zhang et al.,
2003). It is therefore possible that SMN deficiency has other
consequences on RNA metabolism in addition to its effects
on snRNPs and splicing. Significant questions remain, including
whether the change in the snRNP repertoire is the direct cause
of the splicing abnormalities, whether SMN or the SMN
complex has other roles in splicing, and whether the demise
of motor neurons is caused by missplicing of one or several
specific mRNAs or by the cumulative effect of many splicing
abnormalities.Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 783
binding activity is required (Chen et al., 2007). QKI is a strong
candidate gene for schizophrenia susceptibility, based on
genetic linkage data as well as mRNA expression studies. These
findings demonstrate reduced expression of QKI mRNA as well
as putative QKI target mRNAs in disease-relevant regions from
postmortem patient brain tissue samples (Lauriat et al., 2008).
Interestingly, a large-scale analysis of interactions among
proteins associated with inherited ataxias identified a number
of RNA-binding protein families, including QKI as well as Nova
and Fox (Lim et al., 2006). Nova is one of the best-characterized
regulators of an alternative splicing network, coordinating
expression of proteins modulating synaptic function (Ule et al.,
2005), and Fox is an important splicing regulator in several
tissues, including the brain (Underwood et al., 2005). An analysis
of the Fox splicing regulatory network identified thousands of
putative targets with enrichment for neuromuscular functions
and genes associated with diseases affecting neurons and stri-
ated muscle where Fox expression is high (Zhang et al.,
2008a). In addition, mutations in the A2BP1/FOX-1 gene are
associated with mental retardation, epilepsy, and autism (Bhalla
et al., 2004; Sebat et al., 2007), strongly suggesting a direct role
in disease. Both Nova and Fox proteins are likely to have other
RNA processing roles, such as regulating alternative polyadeny-
lation site selection (Licatalosi et al., 2008). These results are
highly suggestive of further roles of RNA-binding proteins in
causing and modifying the severity of neurological diseases.
Splicing Abnormalities in Cancer
Disruption of splicing has long been thought of as a hallmark of
a variety of cancers; however, recent computational analyses
using cancer-derived expressed sequence tags (ESTs) found
that the prevalence of alternatively spliced genes was slightly
lower in tumors compared to normal tissue. What differed
between normal and cancerous tissues were the sets of genes
rather than the number of alternatively spliced genes (Kim
et al., 2008). The major difficulty has been to determine whether
the splicing changes detected in cancer are pathogenic;
however, the cause-effect relationships between the production
of cancer-associated splice variants and cancer formation and
progression are becoming clearer. Cis-acting mutations cause
aberrant splicing and inappropriate expression of cancer-asso-
ciated genes. Several genes use a balance between hnRNP
and SR proteins to regulate alternative splicing, producing
appropriate ratios of pro- and antiapoptotic isoforms (Srebrow
and Kornblihtt, 2006). However, it has also become clear that
the misregulation of alternative splicing in cancer cells is
extremely complex in that the effects of a splicing regulator on
the same splicing event can differ between cells. A test of the
effects of knockdown of 14 hnRNP proteins on 56 alternative
splicing events of apoptotic genes in three cancer/immortalized
cell lines revealed a surprisingly high level of cell line-specific
effects (Venables et al., 2008). The results indicate that cell-
specific differences in trans-acting regulatory environments
make it difficult to predict the effects of changes in individual
splicing factors.
Despite these complexities, strong links have been estab-
lished between altered expression of specific splicing factors,
aberrant splicing of their pre-mRNA targets, and induction of
signaling pathways that are relevant to transformed or malignant784 Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc.cellular phenotypes. A particularly coherent picture has emerged
for the SR protein SF2/ASF, which is elevated in several cancers
and induces transformation when overexpressed at low levels.
SF2/ASF overexpression induces splicing to produce an onco-
genic isoform of the ribosomal protein S6 kinase-b1 (S6K1),
a regulator of translation, and knockdown experiments demon-
strated that expression of this isoform is required for transforma-
tion by SF2/ASF (Karni et al., 2007). Elevated SF2/ASF also
promotes splicing of the RON kinase to a constitutively active
form that has been associated with invasive behavior in several
cancers. The effect of SF2/ASF on RON splicing is direct via
binding to an ESE within the downstream exon. The invasive
phenotype of human cancer cells is reversed by knockdown of
endogenous SF2/ASF or the constitutively active RON splice
variant (Ghigna et al., 2005). Expression of a number of other
splicing factors is also altered in cancer (Grosso et al., 2008);
however, the relevance to cancer formation or progression
remains to be established. It is also important to consider that
most if not all proteins that regulate splicing are multifunctional.
For example, recent results suggest that transformation induced
by SF2/ASF could occur by a mechanism that is independent of
splicing (Karni et al., 2008).
Importantly, cancer-related changes in splicing and splicing
factors are nevertheless potentially useful biomarkers for cancer
diagnosis and classification. Tumor classification is critical for
accurate diagnosis, prognosis, selection of the most effective
therapeutic approach, and follow-up treatment. Analysis of
global alternative splicing patterns by high-throughput RT-PCR,
splicing-sensitive microarrays, and deep sequencing provides
the opportunity for an analysis of unprecedented specificity to
link molecular signatures to predictions of therapeutic efficacy.
Disruption of Alternative Splicing by an RNA Gain
of Function
In an unexpected twist for a molecule thought of as a passive
substrate, RNA expressed from a mutated allele can be patho-
genic. This is a not so subtle reminder that RNA is an intrinsically
potent molecule. This mechanism of disease is observed in
a class of so-called microsatellite expansion disorders. Microsa-
tellites are short (1 to 10 nucleotide) repeats that vary in number
between individuals and cause disease when located in a gene
and expand beyond a normal threshold number of repeats.
The expansions can cause disease by three mechanisms, which
are not mutually exclusive: loss of protein function, gain of aber-
rant protein function due to expansion of triplet repeats within the
open reading frame, and gain of function of the RNA containing
the expansion (Orr and Zoghbi, 2007). There is clear evidence for
an RNA gain of function in four human diseases: myotonic
dystrophy types 1 (DM1) and 2 (DM2), fragile X-associated
tremor ataxia syndrome (FXTAS), and spinocerebellar ataxia 8
(SCA8). An RNA gain-of-function mechanism is also likely in
SCA10, SCA12, andHuntington’s disease-like 2 (HDL2) (Figure 3)
(O’Rourke and Swanson, 2008).
The pathogenic mechanism of an RNA gain of function is best
characterized for DM1, in which a CUG repeat located within the
30 UTR of the DMPKmRNA expands beyond its normal range of
5–38 repeats to a pathogenic range of 50 to more than 2500
repeats. This mutation results in the second most common
cause of muscular dystrophy, as well as a variety of multisyste-
mic features that include cardiac arrhythmias and central
nervous system dysfunction. An early hypothesis, proven to be
correct, was that the RNA repeats disrupt the functions of
specific RNA-binding proteins in trans (Timchenko et al., 1996;
Wang et al., 1995). Proteins identified on the basis of their affinity
for CUG RNA repeats include CUG binding protein 1 (CUGBP1)
andmuscleblind-like 1 (MBNL1) (O’Rourke and Swanson, 2008).
Both proteins, or their paralogues in the CELF and MBNL gene
families, are regulators of several aspects of nuclear and cyto-
plasmic RNA processing, including alternative splicing, mRNA
stability, translation,mRNA localization, andediting (Barreauetal.,
2006; Pascual et al., 2006). The best-characterized pathogenic
effect of expanded CUG RNA is its disruption of a program of
postnatal splicing transitions in striated muscle. At the heart of
thismechanism is thedisruptedbalanceof antagonistic regulation
by MBNL1 and CUGBP1 (Figures 3B and 3C). The result is the
inappropriate expression of embryonic rather than adult splice
variants in adult tissues and consequent manifestations of
disease.
A dramatic cellular hallmark of DM1 is the accumulation of
expanded CUG RNA in nuclear foci. In one of two pathogenic
effects of the RNA, MBNL1 colocalizes with the RNA foci and
is depleted from the nucleoplasm more than 2-fold, resulting
in aberrant regulation of MBNL1-sensitive splicing events
(Figure 3B) (Lin et al., 2006). Interestingly, MBNL1 binds to the
expanded CUG repeats because the RNA forms an extended
stable hairpin structure that resembles its natural intronic binding
site found near targeted alternative exons (Warf and Berglund,
2007; Yuan et al., 2007). Mouse models that produce Mbnl1
Figure 3. RNA Gain of Function
(A) Microsatellite expansions within transcribed
regions with confirmed or potential RNA gain-of-
function effects. The type and number of nucleo-
tide repeats are indicated. (Fragile X-associated
tremor ataxia syndrome, FXTAS; premature
ovarian insufficiency, POI; Huntington’s disease,
HD; spinocerebellar ataxias, SCAs; dentatorubral
pallidoluysian atrophy, DRPLA; spinal and bulbar
muscular atrophy, SBMA; Huntington’s disease-
like 2, HDL2.)
(B) Sequestration of MBNL1 in myotonic dys-
trophy (DM1).
(C) Activation of protein kinase C (PKC) by the
expanded CUG RNA induces hyperphosphoryla-
tion of CUGBP1, which stabilizes the protein.
depletion by either an Mbnl1 gene
knockout (Mbnl1DE3/DE3) or expression
of 250 CTG repeats within a human skel-
etal a actin transgene (HSALR) reproduce
muscle pathology and expression of
embryonic splicing patterns as observed
in DM1 skeletal muscle (Kanadia et al.,
2003; Lin et al., 2006). In the mouse
models and individuals with DM1, the
embryonic splicing pattern for the muscle
specific chloride channel (Clcn1) introduces a premature termi-
nation codon resulting in loss ofClcn1 function and themyotonia
that is characteristic of the disease (Lueck et al., 2007). Delivery
of MBNL1 via adeno-associated virus to HSALR skeletal muscle
reverses the Clcn1 and other splicing changes as well as the
myotonia (Kanadia et al., 2006), demonstrating the link between
MBNL1 depletion and a clinical feature of the disease. A role for
MBNL1 is also supportedby results fromDrosophilaDM1models
in which human MBNL1 homologs suppress the severe pheno-
type induced by CUG repeat RNA in both eye and muscle (de
Haroetal., 2006).DisruptionofMBNL1 functioncouldplayapath-
ogenic role in other microsatellite disorders such as FXTAS, in
whichmale carriers of the fragile X premutation in the FMR1 gene
develop a late-onset neurological syndrome, whereas female
carriers develop premature ovarian insufficiency (POI) (Figure 3A)
(Hagerman and Hagerman, 2004). Nuclear inclusions found in
affected regions of FXTAS brain samples contain MBNL1 as
well as hnRNPA2 (Iwahashi et al., 2006). MBNL1 also colocalizes
with nuclear RNA foci found in neurons from individuals affected
with HDL2 in which the mutated junctophilin-3 (JPH3) gene
contains expanded CTG repeats (Rudnicki et al., 2007).
In addition to depleting RNA-binding proteins, CUG repeat
RNA has the provocative effect of inducing a signaling event re-
sulting in activation of protein kinase C (PKC) (Figure 3C). One
consequence of PKC activation is hyperphosphorylation and
stabilization of CUGBP1 protein, which explains the observa-
tions that CUGBP1 protein is upregulated 2- to 4-fold in DM1
heart and skeletal muscle without an increase in mRNA levels
(Nezu et al., 2007). PKC activation andCUGBP1 hyperphosphor-
ylation and upregulation are direct and rapid effects, as all threeCell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 785
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localization signal. These results convincingly demonstrate that
the ataxin-1-(CAG)82 mRNA alone is not pathogenic in mouse
Purkinje cells (Klement et al., 1998). Strong support for a CAG
RNA gain-of-function mechanism comes from a Drosophila
model in which expression of a truncated pathogenic human
ataxin-3-(CAG)78 mRNA causes neurotoxicity (Li et al., 2008).
The role for RNA toxicity came to light from modifier screens
that identified mbl, the Drosophila MBNL homolog. In addition,
expanded CAG repeats located in the 30 UTR of a heterologous
gene (DsRED), demonstrated not to be expressed as polyQ
protein or CUG antisense RNA, were also pathogenic, directly
demonstrating a pathogenic role for CAG repeat RNA. Expres-
sion of polyQ protein from nonpathogenic interrupted CAA/
CAG repeat RNA induced some pathogenicity, indicating that
both polyQ protein and CAG RNA contribute to the full pheno-
type observed in the fly model. These results open the door for
consideration of RNA gain-of-function effects for expanded
CAG repeats in human disease. Interestingly, whereas MBNL1
suppressed CUG RNA toxicity in the Drosophila DM1 model,
fly and human MBNL1 homologs enhanced the pathogenic
effects of CAG RNA, suggesting different pathogenic mecha-
nisms for CUG and CAG RNA toxicity (Li et al., 2008).
A different set of RNA-binding proteins is associated with
the expanded CGG repeats that cause FXTAS. HnRNP A2 and
Pur-a were identified in purified nuclear inclusions from brains
of a FXTAS mouse model (Jin et al., 2007). Both proteins directly
interact with CGG repeat RNA, and expression of each protein
suppressed the neurodegeneration phenotype in a Drosophila
FXTAS model (Jin et al., 2007). CUGBP1 expression also sup-
pressed the phenotype in flies and was shown to interact with
repeat RNA indirectly by binding to hnRNP A2 (Sofola et al.,
2007). How these proteins fall into amechanism of pathogenesis
is not yet clear. Pur-a knockout mice exhibit an ataxia pheno-
type, consistent with a depletion model in FXTAS; however,
additional effects of the RNA are possible, as demonstrated in
DM1. It is also important to consider that suppression of an
RNA gain-of-function phenotype in Drosophila models, particu-
larly when human proteins are used, could result not only from
restoring the function of a depleted Drosophila protein but also
from rendering the RNA nontoxic by a different mechanism
such as preventing RNA aggregation or interactions that lead
to toxicity. Understanding the specific mechanism of suppres-
sion would provide information regarding the pathogenic mech-
anism of disease as well as potential therapeutic approaches.
RNAs as Therapeutic Targets and Tools
Many approaches have been explored, and many more can be
envisioned to modify the splicing pattern of a mutant pre-
mRNA or eliminate anmRNA that bears a disease-causingmuta-
tion to achieve therapy. Increasing knowledge of RNA biology
and chemistry is stimulating renewed efforts to target the RNA
itself or the splicing and translational machinery as entry points
for therapeutic intervention. Here, we discuss several strategies
including antisense oligonucleotides, antisense snRNAs, RNA
interference, and small molecules (see Analysis by L. Bonetta in
this issue of Cell). Other methods including trans-splicing and
ribozymes will likely emerge as additional options in the future.events were observed 6 hr after induction of a CUG repeat-con-
taining transgene mRNA in heart tissue from an inducible DM1
mouse model (Kuyumcu-Martinez et al., 2007; Wang et al.,
2007). The mechanism by which expanded CUG RNA activates
PKC is unknown. The possibility that PKC activation is
secondary to depletion of MBNL1 is unlikely since neither the
Mbnl1DE3/DE3 nor the HSALR mouse model exhibits elevated
CUGBP1 (Kanadia et al., 2003; Lin et al., 2006). Recent results
demonstrate that a large subset of splicing transitions that occur
during the first 2 weeks of postnatal heart development are
controlled by MBNL1 upregulation and CUGBP1 downregula-
tion. Interestingly, CUGBP1 mRNA levels do not change, and
the 10-fold decrease in protein expression appears to involve
protein dephosphorylation and destabilization (Kalsotra et al.,
2008; Kuyumcu-Martinez et al., 2007). These results suggest
the possibility that expanded CUG repeats are aberrantly stimu-
lating a natural signaling event that maintains CUGBP1 protein
stability in embryonic striated muscle.
DM2 is caused by expanded CCTG repeats in intron 1 of the
ZNF9 gene and is clinically similar to DM1 but is generally less
severe and lacks a congenital form (Liquori et al., 2001). Although
MBNL1 is sequestered on expanded CCUG repeat RNA, which
forms a hairpin structure and accumulates in nuclear foci like
CUG repeat RNA, CUGBP1 is not induced (Lin et al., 2006), sug-
gesting that DM2 is primarily a disease of MBNL depletion. The
lack of CUGBP1 upregulation suggests that PKC is not activated
by expanded CCUG RNA and can provide insights into the cis
requirements for PKC activation by RNA, such as whether
CCUG versus CUG repeats or a gene-specific context is
required.
RNA generated from microsatellite expansions also has the
potential to produce pathogenicity through RNA interference
(RNAi) pathways. Expanded repeats containing CUG, CAG,
and to a lesser extent CCG or CGG, are processed into 21
nucleotide RNAs after folding into single imperfect hairpins that
are cleaved byDicer (Krol et al., 2007). In addition, antisense tran-
scripts have been detected for the expanded repeats of the
DMPK, SCA8, and FMR1 genes (Cho et al., 2005; Ladd et al.,
2007; Nemes et al., 2000), providing a second potential source
of small RNAs. Small CUG or CAG RNAs have been detected in
cells from DM1, SCA1, and Huntington’s disease patients (Cho
et al., 2005; Krol et al., 2007). Evidence for downstream effects
of CUG small interfering RNAs (siRNAs) comes from knockdown
of Dicer in DM1 cells that resulted in elevated levels of normal
endogenous CAG repeat-containing mRNAs (Krol et al., 2007).
Although these results provide a proof of principle, targets rele-
vant to DM1 pathogenesis remain to be identified.
With the exception of SCA12, disease-causing CAG expan-
sions are within open reading frames and result in the production
of proteins containing expanded polyglutamine tracts (polyQ)
(Orr and Zoghbi, 2007). Disease-causing CAG repeat expan-
sions can result in protein loss or gain of function, or both, de-
pending on the gene affected; however, whether expanded
CAG RNA can contribute to pathogenicity depends on the
experimental system. The phenotype observed in a transgenic
mouse model for SCA1 that expresses a pathogenic human
ataxin-1 mRNA containing 82 CAG repeats [ataxin-1-(CAG)82]
is not observed in mice expressing equivalent levels of mRNA
Figure 4. Therapeutic Approaches that Use
or Target RNAs
(A) Antisense oligonucleotides (AOs) or bifunc-
tional AOs that have sequences complementary
to exon 7 conjugated to splicing-enhancing effec-
tors—e.g., serine-arginine (SR) peptide or an ESE
that recruits SR proteins—are used to promote
exon 7 inclusion of the SMN2 gene, decreasing
the production of a truncated SMN protein
(SMND7) and increasing that of a full-length func-
tional protein (SMN).
(B) Modified U1 or U7 snRNA-based vectors can
carry complementary sequences to the targeting
RNAs to achieve the desired splicing pattern. As
shown here, genomic deletions (e.g., from exon
48 to 50) in dystrophin genes of DMD patients
lead to a premature termination codon (STOP) in
exon 51 caused by a frameshift. Antisense U7
snRNA targeting the 30 splice site of exon 51
prevents the inclusion of this exon and restores
the reading frame and, as a result, produces
a partially functional protein.
(C) RNAi approaches are used to eliminate patho-
genicmRNAs. siRNAs delivered to amousemodel
of spinocerebellar ataxia type I (SCA1) elicit degra-
dation and efficient knockdown of the disease-
causing ataxin-1 mRNA that contains the
expanded CAG repeats encoding polyglutamine
(polyQ).used bifunctional oligonucleotides that link an antisense
sequence to exon 7 with an ESE and thereby recruit splicing-
enhancing SR proteins or directly couple antisense sequence
to an SR peptide to promote exon 7 inclusion (Figure 4A)
(Cartegni and Krainer, 2003; Skordis et al., 2003). Similar AO
approaches have also been used for DMD (Alter et al., 2006).
There are also several notable examples of the use of AOs to
downregulate specific mRNAs by mechanisms that do not
necessarily involve modulation of splicing. An AO targeted to
a superoxide dismutase 1 (SOD1) mutation that causes the
neurodegenerative disease amyotrophic lateral sclerosis (ALS)
administered to mice with the disease reduces mutant SOD1
mRNA and protein levels and slows disease progression (Smith
et al., 2006).
Although proof-of-concept experiments for efficacy of AOs
have been demonstrated for manymodel systems and diseases,
only a handful have reached the level of practical therapies in hu-
mans (see Analysis by L. Bonetta in this issue of Cell). One
successful clinical application of AOs is the development of the
first FDA-approved antisense drug that targets cytomegalovirus
(CMV) mRNAs to treat retinitis caused by CMV (Holmlund, 2003).
The major bottlenecks in implementing AOs as therapeutics
relate to tissue-specific delivery of sufficient amounts of the
AOs to achieve a readministration regimen that will sustain ther-
apeutic levels and stability long term. AOswith various backbone
chemistries—morpholino, peptide nucleic acid (PNA), locked
nucleic acid (LNA), 20-O-methyl, thiophosphate, and numerous
other oligonucleotides in place of the naturally occurring phos-
phodiester ribo- or deoxynucleotides—have been developed
to improve affinity, boost stability in the circulation and in target
cells, and enhance cell penetration and nuclear accumulation
(Karkare and Bhatnagar, 2006). Improved tissue-specificAntisense Oligonucleotides
Antisense oligonucleotides (AOs) have been used extensively to
redirect splicing of a mutation-bearing pre-mRNA to prevent it
from generating a disease-causing mRNA and forcing it to splice
into a disease-rescuing mRNA (Sazani and Kole, 2003). Gener-
ally, AOs have been designed to hybridize and block one or
more sequences in the target pre-mRNA that are critical for the
particular splicing event that one wishes to inhibit and cause
the splicing machinery to select an alternative pattern whose
outcome is more favorable. To be effective, the AO’s target
RNA sequence needs to be accessible in the native RNP, which
not all sequences are, and it must be specific. However, it is diffi-
cult to predict whether these requirements will be met, as well as
whether the desired splicing switch will be achieved. Thus, many
different AOs need to be tested, and this may require tiling of
many AOs of various lengths across a considerable stretch of
the target pre-mRNA. Examples of disease-causing genes
targeted by AOs in vitro and in cell systems include the b-globin
gene in b-thalassemia, the CFTR gene in cystic fibrosis, and
lamin A in the premature aging disease Hutchinson-Gilford pro-
geria syndrome (HGPS). Mutations in these genes activate aber-
rant cryptic splice sites and prevent correct pre-mRNA splicing
(Dominski and Kole, 1993; Friedman et al., 1999; Scaffidi and
Misteli, 2005). An AO targeting an exon in the gene encoding
the muscle-specific chloride channel (Clcn1) reverses the defect
of Clcn1 alternative splicing in mouse models of DM1 (Wheeler
et al., 2007). AOs have also been extensively studied as potential
treatment strategies for SMA andDMD. AOs thatmask the ISS or
the 30 splice site of exon 8 of the SMN2 gene have been used to
switch the splice site and promote exon 7 inclusion and thus the
production of a full-length functional SMN protein (Figure 4A)
(Singh, 2007). An interesting mechanism-based approach hasCell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc. 787
delivery has also been achieved by conjugating AOs to peptides
that are selectively taken up by the target tissues (Henke et al.,
2008). AOs remain a promising avenue for the therapy of many
genetic diseases. However, tests for specificity and undesirable
off-target effects must be rigorously and carefully performed.
snRNAs as Vehicles for Stable Antisense RNAs
RNAs can also be used as a tool to target other RNAs, including
pre-mRNAs by antisense hybridization. U1 snRNA- and U7
snRNA-based vectors consisting of the native snRNAs modified
to have an antisense sequence to a target pre-mRNA in place of
the native 50 end of the snRNA have been developed. These
modified snRNAs are transcribed from the corresponding DNA
constructs in the target cells and have unique advantages as
antisense vehicles. Like endogenous snRNAs, they acquire Sm
cores that contribute to their stability, nuclear localization, and
efficient hybridization to complementary target RNAs. Anti-
SMN U7 snRNAs containing sequences complementary to the
30 splice site of exon 8 or to exon 7 linked with an ESE induced
an almost complete and durable correction of SMN2 splicing in
cultured cells (Madocsai et al., 2005) and prolonged survival of
mice with severe SMA (Meyer et al., 2008). Unlike synthetic
AOs, they are RNA, not chemically modified entities, but their
delivery into cells presents unique obstacles that AOs are not
subject to. Viral vectors including recombinant adeno-associ-
ated virus (AAV) and lentiviruses are used as delivery vehicles
to transduce antisense RNAs to the target cells (Danos, 2008).
Systemic administration of AAV U7 or U1 antisense RNA into
a DMDmousemodel leads to the skipping of the exon containing
a mutation causing frameshift and PTC, and to a sustained
production of partially functional dystrophin protein and an
improved phenotype (Figure 4B) (Denti et al., 2006; Goyenvalle
et al., 2004). These results provide the foundation for clinical
phase studies that are currently underway for the treatment of
DMD (Muntoni and Wells, 2007). Another U7 antisense RNA
application is inhibition of HIV-1 production. Lentiviral U7
induces a partial skipping of internal exons encoding the HIV-1
regulatory proteins Tat and Rev (Asparuhova et al., 2007).
However, serious issues remain, including tissue-specific target-
ing and immune response to the viral vectors, as is the case for
conventional gene replacement therapy.
RNA Interference
The capacity to selectively eliminate an mRNA of a disease-
causing allele or to prevent translation of a deleterious protein
by RNAi presents a wide range of targets for therapeutic modu-
lation. RNAi relies on the base pairing interaction of 21–23 nucle-
otide RNAs, a size sufficient to uniquely target an mRNA or even
a specific splice variant, and provides a versatile and potent tool
(Grimm and Kay, 2007). RNAi-based strategies are applicable to
all diseases in which decreasing expression of an RNA, whether
from a mutant allele or an aberrantly expressed mRNA, would
have therapeutic effects. Great progress has been made toward
translating the expertise of RNAi from an extensively used
experimental tool to an effective and safe treatment. The main
challenges again are optimal delivery to the appropriate tissues
and cells, avoiding the cellular antiviral response to double-
stranded RNA, and achieving the optimal balance of high
potency without off-target effects. The three most common
therapeutic approaches to RNAi-based delivery are (1) synthetic788 Cell 136, 777–793, February 20, 2009 ª2009 Elsevier Inc.double-stranded siRNAs applied directly to tissues with a per-
meabilizing vehicle in which exogenous siRNAs become incor-
porated into the endogenous RNAi machinery (RISC complex);
(2) short hairpin RNAs (shRNAs) typically delivered by expression
from viral vectors are expressed in the nucleus, exported to the
cytoplasm by Exportin 5, and processed by Dicer into siRNAs;
and (3) artificial miRNAs, in which the targeting hairpins are ex-
pressed in a pri-miRNA context with viral vectors, processed in
the nucleus by the Drosha-DGCR8 complex, exported to the
cytoplasm, and then processed into functional siRNAs by Dicer
(Rossi, 2008). shRNAs are typically expressed at high levels to
produce highly effective gene silencing, but they can also elicit
toxicity because of saturation of the endogenous RNAi
machinery (Rossi, 2008). Investigations using AAV-delivered arti-
ficial miRNAs to knock down the expanded ataxin-1 mRNA in
a SCA1 mouse model indicate that this approach produced effi-
cient knockdown of this mRNA in cerebellar Purkinje cells
without toxicity (Figure 4C) (Boudreau et al., 2009). These results
provide a next-generation platform for virus-mediated delivery
and expression. RNAi approaches are showing promise in
several other mouse models of disease, including Huntington’s
disease and ALS, and in HIV-infected ‘‘humanized’’ mice. Direct
siRNA delivery is being used in preclinical and clinical trials to
treat several diseases such asmacular degeneration, respiratory
syncicial virus (RSV) infection, and liver cancer (Aigner, 2007;
Pappas et al., 2008).
With a similar technology to that used to deliver siRNAs, it is
possible to target miRNAs with complementary nucleotide
sequences (anti-miRs). Anti-miRs can be used to block endoge-
nous or exogenous (viral) miRNAs to neutralize their effects.
Delivery into most tissues is difficult, but delivery to the liver
works well. For example, the highly expressed and liver-specific
miR-122 was found to have at least two features relevant to
disease: it is required for hepatitis C virus replication in cultured
hepatocytes, and it is involved in regulating cholesterol metabo-
lism. Delivery of LNA-modified oligonucleotides to block miR-
122 demonstrated both the loss of miR-122 and a functional
consequence of lowered plasma cholesterol in mice and
monkeys (Elmen et al., 2008). The potential benefits of this
approach for treating hypercholesterolemia as well as acute
and chronic hepatitis C infections are quite promising.
There are cautionary tales as well, however. In preclinical
testing in mice, naked siRNAs targeting VEGF or the VEGF
receptor and delivered directly to the large chamber of the eye
prevented the over-proliferation of blood vessels in the retina
that cause some forms of macular degeneration (Reich et al.,
2003; Shen et al., 2006). This approach has progressed to phase
I clinical trials in humans (Whelan, 2005). However, tests in mice
designed to determine how ‘‘naked’’ siRNAs are taken up into
cells discovered that siRNAs do not actually enter cells but rather
reduce vascularization through binding to the extracellular Toll-
like receptor 3 and stimulating the NF-kB pathway (Kleinman
et al., 2008). The results highlight the potential for adverse effects
from systemic delivery and the importance of delivery systems
that facilitate entry into the intended cells.
Small Molecules
Alternative splicing is an attractive target for pharmacological
modulation with small molecules. As splicing of most introns is
subunit, and induce translation read-through of termination
codons (Hainrichson et al., 2008; Zingman et al., 2007). Clinical
trials using aminoglycosides for treating several inherited
diseases, including the use of gentamicin to treat DMD and
CF, have provided encouraging results. However, the high levels
of drug required can produce significant side effects as well as
increasing the levels of PTC-containing mRNAs because of inhi-
bition of nonsense-mediated decay (Zingman et al., 2007). The
design of aminoglycosides with improved activity and specificity
holds considerable promise (Hainrichson et al., 2008). A structur-
ally unrelated compound, PTC124, was identified by its suppres-
sion of a PTC-containing luciferase reporter in a high-throughput
screen and has been shown to increase production of the dystro-
phin protein from PTC-containing mRNAs in cultured cells and in
a DMDmouse model (Welch et al., 2007). It is orally bioavailable,
and is currently in clinical trials for DMD (Kerem et al., 2008).
Although nonsense suppression appears to be a potentially
viable therapeutic approach, the possibility that a drug affects
translation termination in other mRNAs in addition to the in-
tended target needs to be carefully evaluated. The potential for
side effects is particularly important in diseases in which life-
long administration of the drug will be necessary.
Concluding Remarks
Disrupted functions of RNAs and RNPs are the cause of
numerous maladies, and they provide a wealth of new opportu-
nities for therapies as well as tools for treatment of human
diseases.We have argued here that the intricate process of alter-
native splicing, in particular, while providing tremendous advan-
tages in affording an almost explosive capacity for generating
transcriptome and proteome diversity, is also fraught with the
risk of malfunction. In many cases, RNAs and RNPsmay provide
a more readily accessible target for therapy than the defective or
deficient proteins they encode. Reversal of defective protein or
RNA toxicity or restoration of normal activity levels could poten-
tially be achieved more specifically and efficaciously by elimi-
nating or redirecting the splicing of the pre-mRNA. Much, in
fact most, of what has been learned came from basic research
on the biology and chemistry of RNAs and the proteins they
interact with in the cellular environment. It is in the public’s
interest that such fundamental research should be vigorously
supported.
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